Bayesian Capital Management made a big biotech play, grabbing 43,000 shares of Amgen worth over $11 million, making it their ...

The Dow Jones Industrial Average is trading down Tuesday afternoon with shares of Merck and Amgen seeing the biggest declines for the blue-chip average.

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

Shares of Merck Merck & Co. Inc. and Amgen Amgen Inc. are contributing to the blue-chip gauge's intraday decline, as the Dow Dow Jones Industrial Average was most recently trading 378 points (0.9%) ...

Investors face an anxious wait to learn what potential levies will mean for Eli Lilly, Pfizer, and other pharma ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, ...

PDT Partners gave Amgen a big fourth-quarter vote of confidence, ramping up its stake by a whopping 480.6%. Institutional ...

Amgen's fundamentals stay strong with rising EPS, dividend yield, and new drug momentum, despite technical pullbacks. See why ...

Every week, reporter Jim Weiker rounds up the biggest business news of the week in his Breaking Ground newsletter. Check out his latest.

Amgen’s adjusted earnings per share reached $4.90, exceeding expectations and marking a 24% increase year-over-year. Total ...